Stay updated with breaking news from Path Inc. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
UiPath (NASDAQ:PATH – Get Rating) had its price objective reduced by Mizuho from $70.00 to $40.00 in a research report sent to investors on Thursday morning, The Fly reports. They currently have a buy rating on the healthcare company’s stock. Other research analysts also recently issued research reports about the company. Berenberg Bank upgraded UiPath […]
UiPath (NASDAQ:PATH – Get Rating) had its price target cut by BMO Capital Markets from $52.00 to $29.00 in a report released on Thursday, The Fly reports. They currently have a market perform rating on the healthcare company’s stock. Several other equities analysts have also recently issued reports on the stock. KeyCorp lowered their target […]
Investors who prefer stability along with decent returns go for large cap stocks. These stocks are of well-known companies with a market capitalization between $10 billion to $200 billion
UiPath (NASDAQ:PATH – Get Rating) had its target price cut by Canaccord Genuity Group from $55.00 to $30.00 in a report released on Thursday morning, The Fly reports. A number of other research analysts have also recently commented on the company. Needham & Company LLC reduced their target price on UiPath from $85.00 to $40.00 […]
UiPath (NASDAQ:PATH – Get Rating) had its price objective dropped by stock analysts at Morgan Stanley from $74.00 to $41.00 in a report issued on Thursday, Benzinga reports. The brokerage presently has an “overweight” rating on the healthcare company’s stock. Morgan Stanley’s price objective points to a potential upside of 84.85% from the stock’s current […]